Indeed, targeting directly BCL2 protein with ABT-199 in combination with LSD1i phenocopied the effects obtained with JAKi in ETP-ALL, which confirmed the central role of JAK/STAT/BCL2 molecular axis in the resistance process of human and mouse ETP-ALL to LSD1i. The gene discussed is BCL2; the disease is acute lymphoblastic leukemia.